Work

Supplementary Data from A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

Year: 2023
Type: supplementary-materials
Abstract: Supplementary Data from A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors
Language: English
Open Access status: gold
OpenAlex ID: W4362431938
Cites:
Cited by:
Related to: 10